Drug intelligence / Profile preview

JSI-401 (CellMed)

Development stage: Preclinical
Lead developer: CellMed
Modality: Small Molecules

Overview

JSI-401 is a synthetic small molecule candidate currently under development by CellMed for the treatment of various inflammatory diseases. Discovered through Computer-Aided Drug Design (CADD) and synthetic design approaches, the drug is part of CellMed's synthetic drug pipeline. While the specific molecular target remains undisclosed, the development strategy leverages synthetic lethality principles to address inflammatory pathways. The candidate is currently in the development stage, within a pipeline that spans from discovery through mid-to-late-stage clinical trials.

Beyond the preview

Go deeper on JSI-401 (CellMed).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JSI-401 (CellMed).

Explore the full profile